Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Cervical Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
39 drugs · 148 active trials
4 drugs · 53 active trials
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Pembrolizumab | Approved | Phase 3 | 27 | 15 | 5 | 47 | 3 | US | Sep 4, 2014 | Dec 18, 2015 |
| Bevacizumab | Approved | Phase 3 | 20 | 11 | 15 | 61 | 1 | US | Feb 26, 2004 | 2002-04 |
| Topotecan | Approved | Phase 3 | 4 | 1 | 9 | 27 | 2 | EU, US | May 28, 1996 | 1996-12 |
| Tisotumab Vedotin | Approved | Phase 4 | 2 | 1 | 2 | 5 | 2 | EU, US | Sep 20, 2021 | Jun 12, 2018 |
| Cisplatin | Phase 4 | Phase 4 | 38 | 18 | 51 | 160 | 0 | — | — | 1996-12 |
| Tucatinib | Phase 4 | Phase 4 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 6, 2026 |
| Paclitaxel | Phase 3 | Phase 3 | 29 | 12 | 40 | 104 | 0 | — | — | 1994-03 |
| Carboplatin | Phase 3 | Phase 3 | 25 | 11 | 26 | 76 | 0 | — | — | 1999-11 |
| Gemcitabine | Phase 3 | Phase 3 | 9 | 4 | 12 | 24 | 0 | — | — | 2000-09 |
| Olaparib | Phase 3 | Phase 3 | 9 | 2 | 3 | 13 | 0 | — | — | Apr 14, 2010 |
| Nab-paclitaxel | Phase 3 | Phase 3 | 8 | 7 | 3 | 16 | 0 | — | — | 2006-05 |
| Atezolizumab | Phase 3 | Phase 3 | 7 | 2 | 2 | 20 | 0 | — | — | Mar 3, 2017 |
| Doxorubicin | Phase 3 | Phase 3 | 6 | 1 | 4 | 16 | 0 | — | — | 1997-11 |
| Chemotherapy | Phase 3 | Phase 3 | 6 | 5 | 2 | 9 | 0 | — | — | Mar 9, 2012 |
| Cediranib | Phase 3 | Phase 3 | 6 | 0 | 2 | 8 | 0 | — | — | 2010-02 |
| Camrelizumab | Phase 3 | Phase 3 | 5 | 3 | 1 | 11 | 0 | — | — | Jan 19, 2019 |
| Lenvatinib | Phase 3 | Phase 3 | 5 | 3 | 1 | 5 | 0 | — | — | Aug 2, 2021 |
| Docetaxel | Phase 3 | Phase 3 | 4 | 2 | 1 | 13 | 0 | — | — | 1997-12 |
| Oxaliplatin | Phase 3 | Phase 3 | 3 | 0 | 3 | 15 | 0 | — | — | 1999-05 |
| Serplulimab | Phase 3 | Phase 3 | 3 | 2 | 1 | 6 | 0 | — | — | Sep 30, 2022 |
| Letrozole | Phase 3 | Phase 3 | 3 | 1 | 2 | 5 | 0 | — | — | 2013-09 |
| Cyclophosphamide | Phase 3 | Phase 3 | 2 | 1 | 2 | 17 | 0 | — | — | 1999-11 |
| Durvalumab | Phase 3 | Phase 3 | 2 | 0 | 1 | 10 | 0 | — | — | Dec 19, 2013 |
| Pemetrexed | Phase 3 | Phase 3 | 2 | 1 | 4 | 8 | 0 | — | — | 2004-08 |
| Pegfilgrastim | Phase 3 | Phase 3 | 2 | 2 | 1 | 4 | 0 | — | — | 2000-07 |
| Fluorouracil | Phase 3 | Phase 3 | 1 | 0 | 5 | 23 | 0 | — | — | 1997-05 |
| Leucovorin | Phase 3 | Phase 3 | 1 | 0 | 2 | 13 | 0 | — | — | 1999-05 |
| Irinotecan | Phase 3 | Phase 3 | 1 | 0 | 5 | 11 | 0 | — | — | 1999-11 |
| Capecitabine | Phase 3 | Phase 3 | 1 | 0 | 1 | 8 | 0 | — | — | 2001-04 |
| Nimotuzumab | Phase 3 | Phase 3 | 1 | 0 | 3 | 7 | 0 | — | — | 2013-01 |
| Filgrastim | Phase 3 | Phase 3 | 1 | 1 | 1 | 6 | 0 | — | — | 1996-12 |
| Vinorelbine | Phase 3 | Phase 3 | 1 | 0 | 4 | 6 | 0 | — | — | 1996-07 |
| Trastuzumab | Phase 3 | Phase 3 | 1 | 0 | 1 | 4 | 0 | — | — | 2014-12 |
| Mitomycin | Phase 3 | Phase 3 | 1 | 1 | 2 | 3 | 0 | — | — | 1997-12 |
| Pertuzumab | Phase 3 | Phase 3 | 1 | 0 | 1 | 3 | 0 | — | — | 2014-12 |
| Adjuvant Chemotherapy | Phase 3 | Phase 3 | 1 | 1 | 2 | 2 | 0 | — | — | Jan 11, 2016 |
| Immunotherapy | Phase 3 | Phase 3 | 1 | 1 | 1 | 2 | 0 | — | — | Mar 1, 2025 |
| Dexamethasone | Phase 3 | Phase 3 | 0 | 0 | 2 | 3 | 0 | — | — | 2011-06 |
| Epirubicin | Phase 3 | Phase 3 | 0 | 0 | 2 | 3 | 0 | — | — | 2014-01 |
| Ifosfamide | Phase 3 | Phase 3 | 0 | 0 | 2 | 2 | 0 | — | — | 1997-12 |
| Bleomycin | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 1997-12 |
| Methotrexate | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 1997-12 |
| Vinblastine | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 1997-12 |
| Vincristine | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 1996-12 |
| Vindesine | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 1997-12 |
| Nivolumab | Phase 2 | Phase 2 | 12 | 4 | 0 | 20 | 0 | — | — | May 18, 2015 |
| Ipilimumab | Phase 2 | Phase 2 | 4 | 2 | 0 | 10 | 0 | — | — | Oct 1, 2012 |
| Tislelizumab | Phase 2 | Phase 2 | 4 | 2 | 0 | 6 | 0 | — | — | Feb 15, 2021 |
| Toripalimab | Phase 2 | Phase 2 | 4 | 3 | 0 | 6 | 0 | — | — | Aug 1, 2021 |
| Aldesleukin | Phase 2 | Phase 2 | 3 | 3 | 0 | 11 | 0 | — | — | 1996-02 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.